1. Home
  2. AWK vs BIIB Comparison

AWK vs BIIB Comparison

Compare AWK & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AWK
  • BIIB
  • Stock Information
  • Founded
  • AWK 1886
  • BIIB 1978
  • Country
  • AWK United States
  • BIIB United States
  • Employees
  • AWK N/A
  • BIIB N/A
  • Industry
  • AWK Water Supply
  • BIIB Biotechnology: Pharmaceutical Preparations
  • Sector
  • AWK Utilities
  • BIIB Health Care
  • Exchange
  • AWK Nasdaq
  • BIIB Nasdaq
  • Market Cap
  • AWK 25.4B
  • BIIB 25.1B
  • IPO Year
  • AWK 2008
  • BIIB 1991
  • Fundamental
  • Price
  • AWK $125.73
  • BIIB $149.02
  • Analyst Decision
  • AWK Hold
  • BIIB Buy
  • Analyst Count
  • AWK 8
  • BIIB 26
  • Target Price
  • AWK $141.88
  • BIIB $248.00
  • AVG Volume (30 Days)
  • AWK 1.2M
  • BIIB 1.6M
  • Earning Date
  • AWK 02-12-2025
  • BIIB 02-11-2025
  • Dividend Yield
  • AWK 2.43%
  • BIIB N/A
  • EPS Growth
  • AWK 3.70
  • BIIB 10.05
  • EPS
  • AWK 5.03
  • BIIB 11.06
  • Revenue
  • AWK $4,515,000,000.00
  • BIIB $9,607,500,000.00
  • Revenue This Year
  • AWK $8.74
  • BIIB N/A
  • Revenue Next Year
  • AWK $5.93
  • BIIB N/A
  • P/E Ratio
  • AWK $24.97
  • BIIB $13.47
  • Revenue Growth
  • AWK 9.24
  • BIIB N/A
  • 52 Week Low
  • AWK $113.34
  • BIIB $145.07
  • 52 Week High
  • AWK $150.68
  • BIIB $268.30
  • Technical
  • Relative Strength Index (RSI)
  • AWK 32.93
  • BIIB 32.44
  • Support Level
  • AWK $122.71
  • BIIB $145.07
  • Resistance Level
  • AWK $126.31
  • BIIB $149.92
  • Average True Range (ATR)
  • AWK 2.32
  • BIIB 3.81
  • MACD
  • AWK -0.43
  • BIIB 0.05
  • Stochastic Oscillator
  • AWK 29.90
  • BIIB 22.51

About AWK American Water Works Company Inc.

American Water Works is the largest investor-owned us water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's nonregulated business is water services for military bases, which operates under long-term contracts with regulated-like returns.

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Share on Social Networks: